Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering

Seres Therapeutics, Inc. Announces Pricing of Initial Public Offering

June 25, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. today announced the pricing of its initial public offering of 7,430,555 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Seres Therapeutics. In addition, Seres Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,114,583 shares of common stock from the company at the public offering price.

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

June 24, 2015

 – Third IDH Mutant Inhibitor to Enter Clinical Trials –

– Brain Penetration and Pan-IDHm Inhibition Broaden Development Options for IDH Mutant-Positive Cancers, Including Gliomas –

BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811

BIND Therapeutics Announces FDA Authorization of First-in-Human Clinical Trial with AstraZeneca's Aurora B Kinase Inhibitor Accurin AZD2811

June 23, 2015

− Collaboration with AstraZeneca results in second Accurin candidate to enter clinical development −

− Promising AZD2811 Data Demonstrating Tumor Growth Inhibition and Prolonged Drug Exposure Recently Presented at 2015 American Association of Cancer Research (AACR) Annual Meeting −

T2 Biosystems Presents Data From Two Studies Evaluating T2MR in Hemostasis at the International Society on Thrombosis and Haemostasis Annual Congress

T2 Biosystems Presents Data From Two Studies Evaluating T2MR in Hemostasis at the International Society on Thrombosis and Haemostasis Annual Congress

June 23, 2015

Rapid, Accurate Multiplex Results Achieved Using Low Blood Volumes on a Single Easy-to-Use Instrument

Joule Expands Intellectual Property on Direct Conversion of CO2 to Hydrocarbons

Joule Expands Intellectual Property on Direct Conversion of CO2 to Hydrocarbons

June 16, 2015

Bedford, Mass -- Joule, the pioneer of liquid fuels from recycled CO2, today announced the issuance of an additional patent on the direct, continuous production of hydrocarbon fuels – extending its ability to target the highest-value molecules of the petroleum distillation process and generate them on demand from sunlight and CO2.

U.S. Patent #9,034,629, issued on May 19, covers both the cyanobacterium and the process for directly converting CO2 into medium-chain alkanes, which are the molecular basis of diesel, jet fuel and gasoline.

Acceleron Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

Acceleron Announces Publication in Cancer Research Demonstrating Dalantercept Prevents Metastases in Preclinical Studies of Breast Cancer

June 15, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that new study findings involving the use of dalantercept to block the activin receptor-like kinase 1 (ALK1) pathway for the treatment of metastatic breast cancer were published in the June 15th issue (volume 75, #12) of Cancer Research, a journal of the American Association for Cancer Research.

Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors

Seres Therapeutics, Inc. Elects Dennis Ausiello, M.D., to Board of Directors

June 11, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company developing a novel class of Ecobiotic® drugs designed to treat disease by restoring the function of a dysbiotic microbiome, today announced that Dennis Ausiello, M.D., has been elected to the company’s board of directors. Dr.

Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109

Seres Therapeutics Receives FDA Breakthrough Therapy Designation for Its Lead Product Candidate, SER-109

June 12, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc., a leading microbiome therapeutics platform company, today announced that SER-109 (Firmacute Eubacterial Spores, Purified Suspension, Encapsulated), its lead product candidate under investigation for the prevention of recurrent Clostridium difficile infection (CDI) in adults, has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA).

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association

June 12, 2015

 - In lower risk myelodysplastic syndromes patients, longer-term treatment with luspatercept led to sustained increases in hemoglobin levels and transfusion independence -

BIND Therapeutics and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

BIND Therapeutics and Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin™ Nanoparticle Using Manocept™ Macrophage Targeting Platform

June 12, 2015

 - Potential for combined Manocept and Accurin platforms to target the tumor microenvironment -